Stockscreener 앱 받기
16.65
2.97%
-0.51
시간 외 거래:
16.76
0.11
+0.66%
전일 마감가:
$17.16
열려 있는:
$16.94
하루 거래량:
2.80M
Relative Volume:
1.05
시가총액:
$1.75B
수익:
$2.20B
순이익/손실:
$-842.79M
주가수익비율:
-1.9732
EPS:
-8.4382
순현금흐름:
$-332.39M
1주 성능:
-2.29%
1개월 성능:
-10.44%
6개월 성능:
-4.48%
1년 성능:
-79.18%
1일 변동 폭
$16.45
$17.18
1주일 범위
$16.27
$17.59
52주 변동 폭
$10.41
$80.26
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
16.65 | 1.80B | 2.20B | -842.79M | -332.39M | -8.4382 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst - Stocktwits
Sarepta cleared to re-submit sNDAs for Amondys and Vyondys - The Pharma Letter
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
Sarepta (SRPT) sNDA Filing Indicates Positive Outlook - GuruFocus
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer - MarketBeat
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Sarepta (SRPT) Plans sNDA Submissions for Duchenne Therapies - GuruFocus
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026 - StreetInsider
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - itemonline.com
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
KROS: Is the Discount Book Value a Value Trap? - TradingView
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study - TradingView
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - BioSpace
Sarepta (SRPT) Advances ENDEAVOR Study with New Cohort - GuruFocus
Sarepta announces that screening and enrollment are underway in Endeavor cohort 8 to evaluate enhanced immunosuppression regimen as part of Elevidys gene therapy for non-ambulant individuals with Duchenne - marketscreener.com
Sarepta begins trial testing sirolimus with gene therapy - Investing.com
Sarepta begins enrollment for enhanced safety protocol in gene therapy study - StreetInsider
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy - Yahoo Finance
Price-Driven Insight from (SRPT) for Rule-Based Strategy - Stock Traders Daily
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness - simplywall.st
Boxer Capital Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Braidwell LP Makes New Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup - TipRanks
Union Square Park Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Quinn Opportunity Partners LLC Increases Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Director Sells $123,207.78 in Stock - MarketBeat
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Mizuho Raises Price Target | SRPT Stock News - GuruFocus
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
Sarepta Therapeutics (SRPT) Maintains 'Outperform' Rating as Miz - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Buys 1,129,610 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
First Trust Advisors LP Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta (SRPT) executive has shares withheld to pay RSU tax - Stock Titan
Reporting person files to sell restricted SRPT shares (SRPT) - Stock Titan
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders - BioSpace
Sarepta (SRPT) CFO has 275 shares withheld to cover RSU tax - Stock Titan
Sarepta (NASDAQ: SRPT) exec has 1,399 shares withheld for taxes - Stock Titan
Sarepta (SRPT) COO has 1,619 shares withheld to cover RSU taxes - Stock Titan
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Sarepta (NASDAQ:SRPT) Healthcare Tech Buzz In Nasdaq Composite - Kalkine Media
Citigroup Raises Price Target for SRPT but Maintains Sell Rating - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Given New $9.00 Price Target at Citigroup - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Market Sentiment Tied To Nasdaq Futures - Kalkine Media
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Why Is uniQure Stock Skyrocketing Monday? - Benzinga
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
Sarepta shares drop after EU regulators reject Elevidys gene therapy - MSN
Sarepta shares drop after FDA asks for more data on Elevidys - MSN
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
Assessing Sarepta Therapeutics (SRPT) Valuation After A Difficult Year For Shareholders - Yahoo Finance
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):